Cargando…
Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery
OBJECTIVE: Despite the development of two significant classifications for recurrence risk evaluation among patients engaged with gastrointestinal stromal tumor and corresponding treatment criteria, recurrence happens in a number of the patients who were once classified as ineligible for treatment an...
Autores principales: | Aznab, Mozaffar, Akhmadi, Sayed Mojtaba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844634/ https://www.ncbi.nlm.nih.gov/pubmed/29373890 http://dx.doi.org/10.22034/APJCP.2018.19.1.39 |
Ejemplares similares
-
Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023) -
Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013) -
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014) -
Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report
por: Tjhoi, Welda E.H., et al.
Publicado: (2019) -
Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)